{"id":475800,"date":"2020-03-24T13:44:01","date_gmt":"2020-03-24T13:44:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=475800"},"modified":"2020-03-24T13:44:01","modified_gmt":"2020-03-24T13:44:01","slug":"ataxia-telangiectasia-market-size-and-share-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/ataxia-telangiectasia-market-size-and-share-delveinsight_475800.html","title":{"rendered":"Ataxia Telangiectasia Market Size and Share | DelveInsight"},"content":{"rendered":"
\"Ataxia<\/a><\/div>\n
DelveInsight’s “Ataxia Telangiectasia (AT) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Ataxia Telangiectasia (AT) , historical and forecasted epidemiology as well as the Ataxia Telangiectasia (AT) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n

(Albany, NY) DelveInsight<\/strong> launched its new report on Ataxia Telangiectasia (AT) – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a><\/p>\n

DelveInsight’s “Ataxia Telangiectasia (AT) – Market Insights, Epidemiology, and Market Forecast-2030<\/strong>” report delivers an in-depth understanding of the Ataxia Telangiectasia (AT), historical and forecasted epidemiology as well as the Ataxia Telangiectasia (AT) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Some of the key facts of the report:<\/strong>
1. Ataxia Telangiectasia occurs in 1 in 40,000–100,000 people worldwide.<\/span>
2. Males and females are affected in equal numbers. In the United States, the prevalence is approximately 1 in 40,000–100,000 live births.<\/span>
3. In the United States, about one per cent of the population is a carrier of a mutation in the Ataxia Telangiectasia mutated kinase (ATM) gene.<\/span>
4. The average Ataxia Telangiectasia prevalence is 1 per 100,000 children. The most reliable estimates for the number of people with Ataxia Telangiectasia, in the UK at least are 3 per million.<\/span><\/p>\n

Key benefits of the report:<\/strong>
1. Ataxia Telangiectasia market report covers a descriptive overview and comprehensive insight of the Ataxia Telangiectasia epidemiology and Ataxia Telangiectasia market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/span>
2. Ataxia Telangiectasia market report provides insights on the current and emerging therapies.<\/span>
3. Ataxia Telangiectasia market report provides a global historical and forecasted market covering drug outreach in 7 MM.<\/span>
4. Ataxia Telangiectasia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Ataxia Telangiectasia market.<\/span><\/span><\/p>\n

\"\"<\/strong><\/span><\/span><\/span><\/p>\n

The key players in Ataxia Telangiectasia market are:<\/strong>
1. EryDel
2. IntraBio
<\/span><\/span><\/span>
The launch of the emerging therapies is expected to significantly impact Ataxia Telangiectasia treatment scenario in the upcoming years:-<\/strong><\/p>\n

Drugs covered:<\/strong>
1. EryDex System<\/span>
2. IB1001<\/span><\/p>\n

Table of contents:<\/strong>
1. Report Introduction<\/span>
2. Ataxia Telangiectasia Market Overview at a Glance<\/span>
3. Ataxia Telangiectasia Executive Summary<\/span>
4. Ataxia Telangiectasia SWOT<\/span>
5. Ataxia Telangiectasia Disease Background and Overview<\/span>
6. Ataxia Telangiectasia Epidemiology and Patient Population<\/span>
6.1. Assumptions and Rationale<\/span>
6.2. 7MM Prevalent cases of Ataxia Telangiectasia (2017–2030)<\/span>
6.3. Diagnosed Cases of Ataxia Telangiectasia (2017–2030)<\/span>
6.4. Treatable Cases of Ataxia Telangiectasia (2017–2030)<\/span>
6.5. Ataxia Telangiectasia Country- Wise Epidemiology<\/span>
6.6. United States<\/span>
6.7. EU-5<\/span>
6.8. Assumptions and Rationale<\/span>
6.9. Germany<\/span>
6.10. France<\/span>
6.11. Italy<\/span>
6.12. Spain<\/span>
6.13. United Kingdom<\/span>
6.14. Japan<\/span>
7. Ataxia Telangiectasia Current Therapies<\/span>
8. Ataxia Telangiectasia Emerging Therapies<\/span>
9. Key Cross Competition<\/span>
9.1. EryDex System: EryDel<\/span>
9.2. IB1001: IntraBio<\/span>
10. Ataxia Telangiectasia Market Size<\/span>
11. 7MM Ataxia Telangiectasia Country-Wise Market Analysis<\/span>
12. United States Market Size<\/span>
13. Germany Market Size<\/span>
14. France Market Size<\/span>
15. United Kingdom Market Size<\/span>
16. Spain Market Size<\/span>
17. Italy Market Size<\/span>
18. Japan Market Size<\/span>
19. Market Drivers<\/span>
20. Market Barriers<\/span>
21. Ataxia Telangiectasia Report Methodology<\/span>
22. DelveInsight Capabilities<\/span>
23. Disclaimer<\/span>
24. About DelveInsight<\/span>
<\/span><\/span><\/p>\n

Related reports:<\/strong><\/p>\n

Ataxia Telangiectasia (AT) – Epidemiology Forecast to 2030<\/span><\/strong><\/a><\/p>\n

Ataxia – Epidemiology Forecast to 2030<\/strong><\/a><\/p>\n

Ataxia – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Yash Bhardwaj
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +919650213330
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Albany
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight’s “Ataxia Telangiectasia (AT) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Ataxia Telangiectasia (AT) , historical and forecasted epidemiology as well as the Ataxia Telangiectasia (AT) market trends in the United States, EU5 … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-475800","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/475800","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=475800"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/475800\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=475800"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=475800"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=475800"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}